Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
about
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Creating an effective clinical registry for rare diseasesConcise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CThe impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Management of Post-Liver Transplant Recurrence of Hepatitis C.Developing therapies to treat hepatitis C infection in post-liver transplant recipients.Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities.IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors.Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney TransplantationChanges in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.We can cure hepatitis C virus after transplant, but what is the best regimen?Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination.Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort.Elimination of Hepatitis C in Liver Transplant Recipients'It's been a long haul, a big haul, but we've made it': hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis
P2860
Q26740319-6F6441DD-4436-4BEF-B082-F67E15DEA35EQ26741126-CBBB200D-864B-4C66-8E7F-D0D878BAF17BQ28075544-4C5A9F5D-CA9A-47D8-B15C-915E25994071Q30235178-291EC56D-660C-42FC-BBA6-F612117C1C6FQ30250096-DF5AF872-0D3F-4D74-B89B-394A90439D4EQ30841159-D7D68391-476F-46D1-8C88-DC03F57338B7Q36165389-4EFCE210-C91B-4588-8D02-E95C9448C464Q36193232-F799DB19-6E86-4C5A-A00B-B40975B7ABDAQ36197501-CF1C556A-3E7E-4A24-AABF-0F74F70258C0Q36676374-CD3BEBB1-6516-4920-BD3A-A262D64EC296Q38384095-FF91B41A-F4E0-455A-B478-81D3106DF143Q38677150-864F401B-BB23-4C84-90A9-EC229BED057EQ38786027-EC5C1541-1B3C-4A63-B5B2-85E441B63E76Q38874771-2FAF9951-C488-426B-BB1A-E4C124C674F4Q38954096-0C51A082-08D5-4BC7-8A86-739D27AA3F07Q39016874-869193D2-03F5-4ED5-A389-7E5ED24F58CCQ39017681-DBE9611B-B733-4DB9-93D2-499D8B2196D9Q39055696-AFCA5A4A-9F9C-4941-ACBB-3758CB428669Q39108672-CFE13927-1D97-46AA-9F6A-66FDD39828F0Q39357015-B2337691-2133-457D-B664-09324C90C71DQ39612358-F2FE2C2E-E578-4DD1-9AEC-5B2BE50CFCBBQ39690146-A0394A4C-9E71-4921-9EFA-7B3429E81478Q39885523-44C6EB46-B90B-441E-90E5-1AEDD5427564Q40118647-1B54FF99-3BC8-402C-B1E7-8FEED64539B0Q40141719-2E0BC8DC-87BB-4384-AA07-4026558A712FQ40316547-2F66726A-1A34-4BFC-8A57-82A851BD56A2Q40352380-BB93F0CE-1EDF-4801-A8AF-8311A6FD7EA9Q40516026-CD0C8B59-89C1-4C2A-BE4E-B28E28F1CCB8Q40598416-8BFAF431-B3FE-41F7-BC3B-A1D55A64F6D9Q40600331-99FAFE47-C9C8-49E5-A1BE-8E0C7719562DQ40635393-246AFF78-D31D-4CC8-A0A6-26FF55208746Q40682194-E154A711-1B15-408D-BB84-1F597C39750AQ44484412-D1091A7C-57D1-45BC-932B-D6A597EE3D5EQ45325786-673C575E-DAD1-4850-9EA0-DCAD2477CD8AQ47570814-0EB2CDE0-95AF-4697-9689-91D8F73FC56AQ55223377-D48DC993-0DA3-4018-A95C-E535B71C2287Q57066937-07D2B337-2662-47BC-B5BD-CD7157521FD8Q58799482-80218065-9751-4B8B-8093-A2FFFEA654A2
P2860
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interferon-free therapy for ge ...... registry and research network.
@en
Interferon-free therapy for ge ...... registry and research network.
@nl
type
label
Interferon-free therapy for ge ...... registry and research network.
@en
Interferon-free therapy for ge ...... registry and research network.
@nl
prefLabel
Interferon-free therapy for ge ...... registry and research network.
@en
Interferon-free therapy for ge ...... registry and research network.
@nl
P2093
P2860
P50
P356
P1476
Interferon-free therapy for ge ...... registry and research network
@en
P2093
Catherine T Frenette
David R Nelson
Giuseppe J Morelli
Hepatitis C Therapeutic Registry Research Network Study Group
Jacqueline G O'Leary
James R Burton
K Rajender Reddy
Michael W Fried
Norah A Terrault
P2860
P356
10.1002/LT.24366
P577
2016-01-01T00:00:00Z